Otherindependent cross-checkabstract only checked I-CHM-09 standard review
Doxorubicin comes from a soil bacterium
Adriamycin, 14-hydroxydaunomycin, a new antitumor antibiotic from S. peucetius var. caesius.
Overview
Arcamone F et al.. Biotechnol Bioeng 1969 · PMID 5365804 · DOI 10.1002/bit.260110607
The 1969 discovery paper names Streptomyces peucetius as the source.
Does the study support the specific claim? No · Methodological quality: moderate
Plain-language summary
Study explained simply
- What did the researchers want to find out?
Report a new antitumour antibiotic.
- How was the study done?
Discovery report.
- What was actually found?
Bacterial origin.
- What do the results mean in everyday life?
Drug origin does not decide whether a drug helps or harms.
- What are the study's limitations?
Title only.
- What does it say about Elawady's specific claim?
Contradicts 'all chemo is fungal'.
- What can explicitly not be concluded from this study?
Efficacy.
Scientific in-depth review
1. Full reference
- Authors
- Arcamone F et al.
- Journal
- Biotechnol Bioeng
- Year
- 1969
- Identifier
- PMID 5365804 DOI 10.1002/bit.260110607
- Verification
- verified – PubMed esummary + efetch 2026-10-25
- Retracted
- no
- Corrections
- none
- Extent checked
- abstract only
- Conflicts of interest and funding
not stated
2. Research question
Isolation of doxorubicin (adriamycin).
3. Study design and population
- Study design
- Other – Original discovery report (title only; no abstract in PubMed)
- Population
not applicable
- Country
Italy (not stated in record)
- Period
1969
- Sample size
not applicable
- Inclusion and exclusion criteria
not applicable
4. Methods and endpoints
- Exposure / intervention
not applicable
- Comparator
not applicable
- Endpoints
not applicable
- Statistical methods
not applicable
5. Actual results
- Results
Title states that adriamycin (doxorubicin) is an antitumour antibiotic from Streptomyces peucetius var. caesius (a bacterium, not a fungus). Only the title was read.
- Absolute risks
not applicable
- Authors' conclusion
not available (title only)
6. Strengths
- Primary source for drug origin
7. Weaknesses
- Only title read
8. Risk of bias
- Orienting tool
- none applicable
- Type of assessment
- simplified assessment (abstract only)
- Full formal assessment
- no
- Overall risk of bias
- not assessable
- Rationale
Not an outcome study.
9. Assessment of the statistical interpretation
Not applicable.
10. Relevance to the specific claim
Shows the anthracycline doxorubicin derives from a Streptomyces bacterium, not a fungus.
11. Independent contrary findings
12. Transferability to Germany and Europe
High.
13. Overall methodological judgement
Sufficient for the origin fact.
| Multidimensional assessment | |
|---|---|
| Authenticity of the source | verified |
| Methodological quality | moderate |
| Risk of bias | not assessable |
| Precision of results | not applicable |
| Directness | direct |
| Reproducibility | unknown |
| Consistency with the overall evidence | unknown |
| Regional transferability | high |
| Adequacy of the interpretation (by the archive) | not applicable |
14. Open questions
15. Linked fact checks
- Chemotherapy drugs (e.g., methotrexate, cisplatin) are fungal products, so using them against one's own cells is illogical. – Studies contradicting or limiting the claim